About 100 reports

  • 6.3 GILEAD
  • Antiviral
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • BUSINESS SEGMENTATION BY REVENUE
  • GILEAD SCIENCES

GS-##, a therapeutic vaccine, generates T-cell immune responses and acts against cells containing HBV antigens in combination with antiviral therapy.

  • Antiviral
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • 6.6 OTHER BRANDED DIRECT-ACTING ANTIVIRALS
  • 7.2 REDUCING THE OVERALL COST BURDEN OF DIRECT-ACTING ANTIVIRAL TREATMENT
  • Antiviral
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Global hepatitis C therapeutics market 2014-2019 ($ millions)
  • Global hepatitis B therapeutics market 2014-2019 ($ millions)

However, choice is limited when it comes to direct-acting antivirals.

  • Antiviral
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Increasing Awareness and Accessibility of Next-Generation Direct-Acting Antivirals...
  • summarizes the most recently recommended treatment regimens for HCV infection in
  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group
  • TREATMENT ACCESS
  • 6.6 CHINA
  • Antiviral
  • Asia
  • Japan
  • Gilead Sciences, Inc.
  • ViiV Healthcare Ltd.

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • 2.2 Pipeline Dominated by Direct-Acting Antivirals
  • 2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class...
  • Antiviral
  • World
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ANTIVIRAL DRUGS MARKET IN EMEA
  • MARKET SIZE AND FORECAST
  • Antiviral
  • World
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • GILEAD SCIENCES IN LIVER CIRRHOSIS THERAPEUTICS MARKET SOVALDI
  • To grow a diversified business To simplify the operating model to increase efficiency

The acquisition includes Novira' s antiviral products, including its lead candidate, NVR ##-##.

  • Antiviral
  • Market Size
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

Applications Covered: - Hepatitis-B antivirals - Hepatitis-C antivirals - Herpes virus - HIV antivirals - Influenza - Other Applications o Pneumonia o Flu End-Users Covered: - Ambulatory Surgical Centers - Clinics - Hospitals Distribution Channels covered: - Hospital Pharmacy Sto

  • Antiviral
  • Asia
  • North America
  • World
  • Forecast
  • Brazil: Fastest Growing Therapy Classes (ATC 3)

BRAZIL IMS Pharmaceutical Pricing & Reimbursement Concise Guide Published March 2017 The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions.

  • Antiviral
  • Therapy
  • Brazil
  • Demand
  • GlaxoSmithKline plc
  • SHARE OF INFECTIOUS DISEASES MARKET IN PHARMACEUTICAL MARKET IN CHINA 2015
  • HIGHLIGHTS

It has direct antiviral activity in tissue culture against RNA viruses.

  • Antiviral
  • China
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • depicts the treatment algorithm recommended by WHO for the management of chronic hepatitis...
  • Management of Hepatitis B Infection
  • Antiviral
  • Therapy
  • World
  • Gilead Sciences, Inc.
  • Tekmira Pharmaceuticals Corporation

MARKET OVERVIEW.............. ## Antivirals.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Infectious Disease Drugs.............. ## Table ##: Infectiou

  • Antiviral
  • Hepatitis
  • Europe
  • Demand
  • Market Shares
  • 6.3.1 Phase II
  • 3. Hepatitis C - Approved Drugs Sales & Forecast

The study will examine the hypothesis that pretreatment viral testing will identify patients who will respond to antiviral therapy with Telaprevir.

  • Antiviral
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Hepatitis C

4546 5000 3864
  • DIRECT-ACTING ANTIVIRALS TARGET KEY VIRAL NON-STRUCTURAL PROTEINS NECESSARY FOR HCV...
  • Pivotal studies supporting approvals of Zepatier
  • Antiviral
  • Asia
  • Europe
  • Japan
  • World

Interferon and Antiviral ##. ##. ##. ##.

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size

MARKET OVERVIEW.............. ## Antiviral Drugs.............. ## Table ##: Antiviral Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others ## Table ##: Hepatitis C Market by Category Worldwide (2015) - Per

  • Antiviral
  • United States
  • World
  • Demand
  • Market Shares
  • 6.2.2 PHASE II CLINICAL TRIALS ANALYSIS
  • 6.4.1 PHASE II CLINICAL TRIALS ANALYSIS
  • Antiviral
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

ANTIVIRAL THERAPY SUPPRESSES THE REPLICATION OF HIV INFECTION IN THE BODY.

  • Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • Ltd. Chengdu Enwei Group Corporation
  • VIRAL INFECTIONS THERAPEUTICS MARKET, GLOBAL, FORECAST ANNUAL REVENUES FOR
  • 4.4.1.4 Failure Rates by Molecular Target

ANTIVIRAL THERAPY TARGETING VIRAL POLYMERASE.

  • Antiviral
  • Therapy
  • World
  • Market Size
  • Gilead Sciences, Inc.

Antivirals?

  • Antiviral
  • Therapy
  • Forecast
  • Market Size
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

Antiviral therapy suppresses the replication of HIV infection in the body.

  • Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • UNAIDS
  • Trial Results

Recurrent D##BB Antivirals ATC Classification Target Patient Details Age Gender Accept Healthy Volunteer(s) Subject(s) Type Participant Criteria (Inclusion) ## Years and older Both No Glucocorticoid Receptor (GR); Viral DNA Polymerase Participant Criteria (Exclusion) Generally good health

  • Antiviral
  • World
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Maruho Co., Ltd.

HIV

4546 5000 3864
  • ATTACHMENT AND FUSION
  • Current Treatment Options

Antiviral Therapy, ##(##), ##-## < DOI> ##. ##/ imp##< / DOI>.

  • Antiviral
  • Europe
  • United States
  • World
  • Bristol-Myers Squibb Company
  • 3.4.2 ANTIVIRAL THERAPY
  • RECOMMENDED ANTIVIRAL REGIMENS FOR THE MANAGEMENT OF GH IN IMMUNOCOMPETENT PATIENTS
  • Antiviral
  • Therapy
  • Japan
  • Forecast
  • Genocea Biosciences, Inc.
  • HIV-1 INFECTION THERAPEUTICS, GLOBAL, SUSPENDED CLINICAL TRIALS, 2014*
  • Trial Results

In preclinical studies, doravirine showed potent antiviral activity against HIV-##.

  • Antiviral
  • World
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

- Where lie the best geographical opportunities for selling those antivirals?

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • Market Size
  • Drug Details
  • Contact Detail(s)

It is an antiviral medicament employed in combination therapy along with other antiviral drugs for the treatment of children and adults aged above two years, who are infected with Human Immunodeficiency Virus type ##.

  • Antiviral
  • Therapy
  • World
  • GlaxoSmithKline plc
  • Merck & Co., Inc.